Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI	10/11/2006 12:46:45 AM
	Read Replies (1) of 3044

Presuming that the board responds tomorrow, perhaps MLNM will see a bump on Thursday (assuming that the board confirms GENZ has the superiour offer.) DOW JONES NEWSWIRES AnorMED Inc. (ANOR) late Tuesday confirmed it received a proposal from Genzyme Corp. (GENZ) raising its bid for AnorMED to $13.50 a share from $8.55. The Canadian biotechnology company said it will review Genzyme's $580 million proposal and have its board determine, after receiving the advice of its financial and legal advisers, whether or not it constitutes a "superior proposal" to a deal with Millennium Pharmaceuticals Inc. (MLNM), which has agreed to buy AnorMED for $515 million, or $12 a share. Earlier Tuesday, Genzyme said it is giving AnorMED until Wednesday to determine if the offer constitutes a superior proposal and until Oct. 17 to execute a support agreement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next